JP Morgan Chase
TSHA icon

JP Morgan Chase’s Taysha Gene Therapies TSHA Stock Holding History

JP Morgan Chase’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Buy
766,282
+11,500
+2% +$68.1K ﹤0.01% 3421
2026
Q1 		$3.07M Sell
754,782
-19,630
-3% -$91.3K ﹤0.01% 3758
2025
Q4 		$4.26M Buy
774,412
+478,168
+161% +$2.32M ﹤0.01% 3468
2025
Q3 		$969K Buy
296,244
+73,595
+33% +$208K ﹤0.01% 4622
2025
Q2 		$514K Sell
222,649
-780,418
-78% -$1.7M ﹤0.01% 4767
2025
Q1 		$1.39M Sell
1,003,067
-1,640,688
-62% -$2.74M ﹤0.01% 4124
2024
Q4 		$4.57M Sell
2,643,755
-357,642
-12% -$742K ﹤0.01% 3436
2024
Q3 		$6.03M Buy
3,001,397
+37,844
+1% +$83K ﹤0.01% 3082
2024
Q2 		$6.64M Buy
2,963,553
+2,869,812
+3,061% +$8.35M ﹤0.01% 2814
2024
Q1 		$269K Buy
93,741
+57,257
+157% +$119K ﹤0.01% 5180
2023
Q4 		$64.6K Buy
36,484
+36,347
+26,531% +$72.5K ﹤0.01% 5916
2023
Q3 		$433 Sell
137
-1,645
-92% -$3.07K ﹤0.01% 6746
2023
Q2 		$1.18K Hold
1,782
– – ﹤0.01% 6437
2023
Q1 		$1K Hold
1,782
– – ﹤0.01% 6557
2022
Q4 		$4K Sell
1,782
-42,776
-96% -$86.6K ﹤0.01% 6215
2022
Q3 		$86K Sell
44,558
-234,733
-84% -$852K ﹤0.01% 5351
2022
Q2 		$1.04M Sell
279,291
-160,513
-36% -$637K ﹤0.01% 4046
2022
Q1 		$2.87M Buy
439,804
+202,245
+85% +$1.51M ﹤0.01% 3475
2021
Q4 		$2.77M Sell
237,559
-182,803
-43% -$2.76M ﹤0.01% 3576
2021
Q3 		$7.83M Buy
420,362
+206,716
+97% +$3.93M ﹤0.01% 2626
2021
Q2 		$4.53M Buy
213,646
+187,423
+715% +$4.32M ﹤0.01% 3141
2021
Q1 		$532K Buy
26,223
+2,475
+10% +$67K ﹤0.01% 4639
2020
Q4 		$630K Buy
+23,748
New +$512K ﹤0.01% 4243

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase's TSHA Position: Q2 2026 in Review

JP Morgan Chase increased its Taysha Gene Therapies (TSHA) stake by 1.5% in Q2 2026, buying an estimated $68.1K and bringing the position to 766,282 shares worth $5.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3421.

JP Morgan Chase first reported a position in TSHA in Q4 2020 and has held it in 23 quarters since. The position peaked at $7.83M in Q3 2021. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • JP Morgan Chase held 766,282 shares of Taysha Gene Therapies worth $5.16M as of Q2 2026.
  • JP Morgan Chase bought 11,500 Taysha Gene Therapies shares in Q2 2026, an estimated $68.1K.
  • Taysha Gene Therapies made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3421 holding.
  • JP Morgan Chase first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Taysha Gene Therapies position peaked at $7.83M in Q3 2021.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.